Header Logo

NUHAD K IBRAHIM

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lin NU, Kumthekar P, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Sussell J, Pegram M. Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. NPJ Breast Cancer. 2023 Nov 17; 9(1):94. PMID: 37978197; PMCID: PMC10656527.
      Citations:    
    2. Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health. 2023 Oct; 19(4):267-273. PMID: 37795002; PMCID: PMC10546803.
      Citations:    
    3. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422. PMID: 37547448; PMCID: PMC10399250.
      Citations:    
    4. Wagner C, Fritsche J, Maurer D, Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-Gonzalez GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Walter S. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945. PMID: 37172100; PMCID: PMC10330623.
      Citations:    Fields:    Translation:HumansCells
    5. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13). PMID: 37444385; PMCID: PMC10339918.
      Citations: 1     
    6. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469. PMID: 37061619.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213. PMID: 37016732.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, ATTAIN Investigators, Di?ras V, M?ller V, Cort?s J. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 07 01; 8(7):1047-1052. PMID: 35552364; PMCID: PMC9100460.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM, Tripathy D, Arun B, Ibrahim NK. Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. NPJ Breast Cancer. 2022 Apr 07; 8(1):46. PMID: 35393462; PMCID: PMC8990006.
      Citations:    
    10. Singareeka Raghavendra A, Kypriotakis G, Karam-Hage M, Kim S, Jizzini M, Seoudy KS, Robinson JD, Barcenas CH, Cinciripini PM, Tripathy D, Ibrahim NK. The Impact of Treatment for Smoking on Breast Cancer Patients' Survival. Cancers (Basel). 2022 Mar 12; 14(6). PMID: 35326615; PMCID: PMC8946483.
      Citations:    
    11. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5). PMID: 35267631; PMCID: PMC8909018.
      Citations:    
    12. Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NT. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep. 2021 11 15; 11(1):22242. PMID: 34782633; PMCID: PMC8593093.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    13. Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P. Reply to J. Wei et al. J Clin Oncol. 2021 12 20; 39(36):4127-4128. PMID: 34637335.
      Citations:    Fields:    
    14. Al-Shamsi HO, Abu-Gheida I, Abdulsamad AS, AlAwadhi A, Alrawi S, Musallam KM, Arun B, Ibrahim NK. Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. Oncologist. 2021 11; 26(11):e2086-e2089. PMID: 34327780; PMCID: PMC8571745.
      Citations:    Fields:    Translation:Humans
    15. Ibrahim NK. Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer. Front Oncol. 2021; 11:617874. PMID: 34295806; PMCID: PMC8290913.
      Citations: 2     
    16. Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P. Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. J Clin Oncol. 2021 08 20; 39(24):2667-2675. PMID: 33945296; PMCID: PMC8376355.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    17. Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK. Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer. Cancers (Basel). 2021 Apr 23; 13(9). PMID: 33922702; PMCID: PMC8123066.
      Citations:    
    18. Alhalabi O, Soomro Z, Sun R, Hasanov E, Albittar A, Tripathy D, Valero V, Ibrahim NK. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. NPJ Breast Cancer. 2021 Mar 19; 7(1):28. PMID: 33742001; PMCID: PMC7979865.
      Citations:    
    19. Mariotti V, Han H, Ismail-Khan R, Tang SC, Dillon P, Montero AJ, Poklepovic A, Melin S, Ibrahim NK, Kennedy E, Vahanian N, Link C, Tennant L, Schuster S, Smith C, Danciu O, Gilman P, Soliman H. Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021 Jan 01; 7(1):61-69. PMID: 33151286; PMCID: PMC7645745.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    20. Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist. 2021 02; 26(2):e230-e240. PMID: 33140515; PMCID: PMC7873313.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    21. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res. 2021 03 01; 27(5):1247-1255. PMID: 33115815; PMCID: PMC9011198.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    22. Gao C, Wang F, Suki D, Strom E, Li J, Sawaya R, Hsu L, Raghavendra A, Tripathy D, Ibrahim NK. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience. Int J Cancer. 2021 02 15; 148(4):961-970. PMID: 32748402.
      Citations: 3     Fields:    Translation:Humans
    23. Bashour SI, Ibrahim NK, Schomer DF, Hess KR, Gao C, Tripathy D, Fuller GN. Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. Br J Cancer. 2020 10; 123(9):1417-1423. PMID: 32747747; PMCID: PMC7591856.
      Citations: 1     Fields:    Translation:Humans
    24. Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. Evolution of Cancer Care in Response to the COVID-19 Pandemic. Oncologist. 2020 09; 25(9):e1426-e1427. PMID: 32536024; PMCID: PMC7323244.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    25. Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. In Reply. Oncologist. 2020 08; 25(8):e1252-e1253. PMID: 32378772; PMCID: PMC7267302.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    26. Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist. 2020 06; 25(6):e936-e945. PMID: 32243668; PMCID: PMC7288661.
      Citations: 262     Fields:    Translation:HumansCellsPHPublic Health
    27. Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 06 15; 26(12):2789-2799. PMID: 31969331.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    28. Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med. 2020 02; 9(3):1025-1032. PMID: 31849202; PMCID: PMC6997080.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    29. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394. PMID: 31461380; PMCID: PMC7351336.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    30. Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, Translational Breast Cancer Research Consortium (TBCRC), Gimenez-Cassina Lopez B. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2. PMID: 31558424; PMCID: PMC7035200.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    31. Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112. PMID: 31097774; PMCID: PMC6738035.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    32. Rugo HS, Twelves C, Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Dieras V, M?ller V, Tagliaferri M, Hannah AL, Cort?s J. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncol. 2019 Jul; 15(19):2211-2225. PMID: 31074641; PMCID: PMC7466911.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    33. Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res. 2019 07 01; 25(13):3996-4013. PMID: 30867218; PMCID: PMC6606366.
      Citations: 35     Fields:    Translation:HumansCells
    34. Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, Translational Breast Cancer Research Consortium. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089. PMID: 30860945; PMCID: PMC6494354.
      Citations: 107     Fields:    Translation:HumansCTClinical Trials
    35. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026. PMID: 29923182; PMCID: PMC6235694.
      Citations: 15     Fields:    Translation:Humans
    36. Al-Awadhi A, Lee Murray J, Ibrahim NK. Developing anti-HER2 vaccines: Breast cancer experience. Int J Cancer. 2018 11 01; 143(9):2126-2132. PMID: 29693245.
      Citations: 12     Fields:    Translation:Humans
    37. Weiss A, Bashour SI, Hess K, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res. 2018 04 16; 20(1):27. PMID: 29661243; PMCID: PMC5902970.
      Citations: 8     Fields:    Translation:Humans
    38. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305. PMID: 29579338.
      Citations: 6     Fields:    Translation:Humans
    39. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400; PMCID: PMC5559961.
      Citations: 6     
    40. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017 06 27; 8:15916. PMID: 28653662; PMCID: PMC5490269.
      Citations: 112     Fields:    Translation:HumansAnimalsCells
    41. Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Oncologist. 2017 05; 22(5):526-534. PMID: 28377466; PMCID: PMC5423520.
      Citations: 8     Fields:    Translation:Humans
    42. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    43. Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+?T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. Ann Surg Oncol. 2017 Aug; 24(8):2161-2167. PMID: 28315060; PMCID: PMC5908243.
      Citations: 12     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    44. Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 2017 04 01; 123(7):1115-1123. PMID: 27893937; PMCID: PMC5372352.
      Citations: 11     Fields:    Translation:HumansCells
    45. Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, Madan RA, Heery CR, Gulley JL, Schlom J. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunol Res. 2016 09 02; 4(9):755-65. PMID: 27485137; PMCID: PMC5138028.
      Citations: 15     Fields:    Translation:HumansCells
    46. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77. PMID: 27287781; PMCID: PMC5989315.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    47. Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S, Translational Breast Cancer Research Consortium. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin Cancer Res. 2016 Dec 01; 22(23):5706-5712. PMID: 27166393.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    48. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52. PMID: 26834058; PMCID: PMC5070554.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    49. Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, Valero V, Ibrahim NK. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLoS One. 2016; 11(1):e0145534. PMID: 26752563; PMCID: PMC4709074.
      Citations: 8     Fields:    Translation:Humans
    50. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL, Mart? JL. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2015 Nov; 1(8):1087-95. PMID: 26291768; PMCID: PMC6622177.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    51. Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer. 2015 Sep 29; 113(7):1003-9. PMID: 26393887; PMCID: PMC4651124.
      Citations: 15     Fields:    Translation:Humans
    52. Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. Cancer. 2015 Nov 15; 121(22):3965-74. PMID: 26249241.
      Citations: 6     Fields:    Translation:HumansCells
    53. Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs. 2015 Aug; 33(4):890-4. PMID: 25947565.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    54. Bashour SI, Ibrahim NK. CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come. Clin Cancer Res. 2015 May 01; 21(9):1975-7. PMID: 25934886.
      Citations: 1     Fields:    Translation:Humans
    55. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. 2015 Oct; 15(5):325-31. PMID: 25913905; PMCID: PMC4568133.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    56. Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015 May; 20(5):466-73. PMID: 25802405; PMCID: PMC4425375.
      Citations: 32     Fields:    Translation:Humans
    57. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer. 2014; 5(5):351-9. PMID: 24723978; PMCID: PMC3982182.
      Citations: 1     
    58. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7. PMID: 24669015; PMCID: PMC4037860.
      Citations: 49     Fields:    Translation:HumansCellsCTClinical Trials
    59. Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. J Cancer. 2013; 4(7):577-84. PMID: 23983823; PMCID: PMC3753533.
      Citations: 35     
    60. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis. 2013 Jun; 30(5):631-42. PMID: 23370825; PMCID: PMC3857726.
      Citations: 16     Fields:    Translation:Humans
    61. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6. PMID: 23242617; PMCID: PMC3867793.
      Citations: 9     Fields:    Translation:Humans
    62. Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H, Xu H, Shi Y, Wang LX, Ross JA, Rodrigues SP, Almeida IC, Yang X, Qu J, Schocker NS, Michael K, Zhou D. MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol. 2012 Dec; 41(6):1977-84. PMID: 23023583; PMCID: PMC3556481.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    63. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5. PMID: 22331946.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    64. Ibrahim N, Yu Y, Walsh WR, Yang JL. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep. 2012 May; 27(5):1303-11. PMID: 22323095.
      Citations: 44     Fields:    Translation:HumansAnimals
    65. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783; PMCID: PMC3233286.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    66. Finn RS, Bengala C, Ibrahim N, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ, Roch? H. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011 Nov 01; 17(21):6905-13. PMID: 22028489.
      Citations: 94     Fields:    Translation:Humans
    67. Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011 Nov 01; 17(21):6888-96. PMID: 21989064.
      Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
    68. Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6822-30. PMID: 21878535.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    69. Zhou D, Levery SB, Hsu FF, Wang PG, Teneberg S, Almeida IC, Li Y, Xu H, Wang LX, Xia C, Ibrahim NK, Michael K. Immunologic mapping of glycomes: implications for cancer diagnosis and therapy. Front Biosci (Schol Ed). 2011 06 01; 3(4):1520-32. PMID: 21622287; PMCID: PMC3548420.
      Citations: 3     Fields:    Translation:HumansCells
    70. Miles D, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Tres A, Murray JL, Ibrahim NK, Roch? H, Mayordomo J, Theratope? Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. PMID: 21572124; PMCID: PMC3228158.
      Citations: 102     Fields:    Translation:HumansCTClinical Trials
    71. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Gomez H, Hubbard R, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF, Cotrina J, Chac?n JI. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81. PMID: 21558518; PMCID: PMC5638042.
      Citations: 305     Fields:    Translation:Humans
    72. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61. PMID: 20829329; PMCID: PMC4181852.
      Citations: 96     Fields:    Translation:Humans
    73. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010 Oct 01; 28(28):4316-23. PMID: 20805453.
      Citations: 102     Fields:    Translation:HumansCells
    74. Ibrahim NK. Ixabepilone development across the breast cancer continuum: a paradigm shift. Cancer Manag Res. 2010 Jun 30; 2:169-79. PMID: 21188108; PMCID: PMC3004591.
      Citations: 5     
    75. Hortobagyi GN, Young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore I. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010 May 15; 116(10):2301-6. PMID: 20225231.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    76. Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol. 2010 Apr 20; 28(12):2032-7. PMID: 20308667.
      Citations: 60     Fields:    Translation:Humans
    77. Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X, Royer B. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer. 2010 Mar 02; 102(5):827-32. PMID: 20160731; PMCID: PMC2833251.
      Citations: 4     Fields:    Translation:HumansCells
    78. Estephan F, Valero V, Esteva FJ, Mejia JA, Frye DK, Ibrahim NK. Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule. Oncology. 2009; 77(1):63-70. PMID: 19556811.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    79. Ibrahim NK, Al Ashakar MS, Gad ZM, Warda MH, Ghanem H. An epidemiological study on survival of oropharyngeal cancer cases in Alexandria, Egypt. East Mediterr Health J. 2009 Mar-Apr; 15(2):369-77. PMID: 19554984.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    80. Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs. 2009; 23(5):277-87. PMID: 19754218.
      Citations: 5     Fields:    Translation:HumansCells
    81. Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009; 11(5):R73. PMID: 19811637; PMCID: PMC2790853.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    82. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008 Jul; 19(7):1242-1248. PMID: 18334512.
      Citations: 76     Fields:    Translation:Humans
    83. Kaur H, Loyer EM, David CL, Sawaf H, DuBrow RA, Ibrahim NK. Radiologic findings in taxane induced colitis. Eur J Radiol. 2008 Apr; 66(1):75-8. PMID: 17553645.
      Citations: 2     Fields:    Translation:Humans
    84. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33. PMID: 17200359.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    85. Pinder MC, Ibrahim NK. Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer. Drugs Today (Barc). 2006 Sep; 42(9):599-604. PMID: 17028669.
      Citations: 8     Fields:    Translation:Humans
    86. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Hortobagyi GN, Pusztai L, G?mez HL. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44. PMID: 16896004.
      Citations: 264     Fields:    Translation:Humans
    87. Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):76-82. PMID: 16765534.
      Citations: 42     Fields:    Translation:Humans
    88. Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist. 2006 Jun; 11(6):553-62. PMID: 16794235.
      Citations: 25     Fields:    Translation:Humans
    89. Davidson N, Ibrahim N, Harries M, Harper P. Albumin-bound Paclitaxel in metastatic breast cancer: viewpoints. Drugs. 2006; 66(7):949-50. PMID: 16740011.
      Citations:    Fields:    Translation:Humans
    90. Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi G, Mettinger KL, Cristofanilli M. Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006 Apr; 57(4):540-4. PMID: 16193332.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    91. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005 Sep 01; 23(25):6019-26. PMID: 16135470.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    92. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91. PMID: 15986399.
      Citations: 81     Fields:    Translation:HumansCTClinical Trials
    93. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85. PMID: 16115903.
      Citations: 602     Fields:    Translation:Humans
    94. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92. PMID: 16087943.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    95. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85. PMID: 15738535.
      Citations: 311     Fields:    Translation:HumansCTClinical Trials
    96. Ibrahim NK. Leukemogenic effect of chemotherapy in patients with breast carcinoma: is it a real concern? Cancer. 2004 Oct 01; 101(7):1479-81. PMID: 15378475.
      Citations: 1     Fields:    Translation:Humans
    97. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13. PMID: 15378497.
      Citations: 7     Fields:    Translation:Humans
    98. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93. PMID: 15136595.
      Citations: 116     Fields:    Translation:Humans
    99. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 07; 25(3):94-102. PMID: 14698135.
      Citations: 128     Fields:    Translation:HumansCTClinical Trials
    100. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res. 2003 Jul; 9(7):2426-34. PMID: 12855614.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    101. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71. PMID: 12784330.
      Citations: 48     Fields:    Translation:Humans
    102. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73. PMID: 12637486.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    103. Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin Breast Cancer. 2003 Feb; 3 Suppl 4:S139-43. PMID: 12620151.
      Citations: 11     Fields:    Translation:Humans
    104. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002 May; 8(5):1038-44. PMID: 12006516.
      Citations: 161     Fields:    Translation:HumansCTClinical Trials
    105. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9. PMID: 12006521.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    106. Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002 Feb; 13(2):218-21. PMID: 11885997.
      Citations: 4     Fields:    Translation:Humans
    107. Ibrahim NK, Rahman Z, Valero V, Murray JL, Frye D, Hortobagyi GN. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest. 2002; 20(1):29-37. PMID: 11852999.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    108. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82. PMID: 11745249.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    109. Ibrahim NK. Commentary on "A review of vinorelbine in the treatment of breast cancer". Clin Breast Cancer. 2001 Oct; 2(3):236. PMID: 11899419.
      Citations:    Fields:    Translation:Humans
    110. Sulkes A, Stemmer SM. Doxorubicin-based chemotherapy in the elderly. Ann Oncol. 2001 Aug; 12(8):1180-1. PMID: 11583205.
      Citations: 1     Fields:    Translation:Humans
    111. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33. PMID: 11454891.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    112. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71. PMID: 11241232.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    113. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66. PMID: 11458813.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    114. Sezer O, Eucker J, Possinger K. Colitis associated with docetaxel-based chemotherapy. Lancet. 2000 May 20; 355(9217):1823-4. PMID: 10832856.
      Citations: 3     Fields:    Translation:Humans
    115. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21. PMID: 10776969.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    116. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22; 355(9200):281-3. PMID: 10675076.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    117. Edeiken BS, Fornage BD, Bedi DG, Singletary SE, Ibrahim NK, Strom EA, Holmes F. US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology. 1999 Dec; 213(3):895-900. PMID: 10580972.
      Citations: 4     Fields:    Translation:Humans
    118. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7. PMID: 10550135.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    119. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7. PMID: 10506711.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    120. Ibrahim NK, Hortobagyi GN. The evolving role of specific estrogen receptor modulators (SERMs) Surg Oncol. 1999 Aug; 8(2):103-23. PMID: 10732962.
      Citations: 4     Fields:    Translation:Humans
    121. Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1999; 43(6):471-8. PMID: 10321507.
      Citations: 8     Fields:    Translation:Humans
    122. Le Chevalier T, Monnier A, Douillard JY, Ruffie P, Sun XS, Belli L, Ibrahim N, Bougon N, B?rille J. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer. 1998 Dec; 34(13):2032-6. PMID: 10070306.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    123. Rosner F. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Sep 01; 83(5):1054-5. PMID: 9731914.
      Citations:    Fields:    Translation:Humans
    124. Ibrahim NK, Hortobagyi GN. New antiestrogens in breast cancer: a review. Breast J. 1998 Jul; 4(4):213-29. PMID: 21223440.
      Citations: 1     Fields:    
    125. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Mar 01; 82(5):965-9. PMID: 9486588.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    126. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 3):S30-3. PMID: 9071338.
      Citations:    Fields:    Translation:Humans
    127. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8. PMID: 8774207.
      Citations: 11     Fields:    Translation:Humans
    128. Hortobagyi GN, Ibrahim N. Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Semin Oncol. 1996 Feb; 23(1 Suppl 1):53-7. PMID: 8629039.
      Citations: 2     Fields:    Translation:Humans
    129. Ibrahim NK, Buzdar AU. Aromatase inhibitors: current status. Am J Clin Oncol. 1995 Oct; 18(5):407-17. PMID: 7572758.
      Citations: 1     Fields:    Translation:HumansAnimals
    130. Ibrahim NK, Abdul-Karim FW. Colorectal adenocarcinoma in young Lebanese adults. The American University of Beirut-Medical Center experience with 32 patients. Cancer. 1986 Aug 01; 58(3):816-20. PMID: 3015371.
      Citations: 5     Fields:    Translation:Humans
    131. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.
    132. Albumin-bound paclitaxel in metastatic breast cancer. Drugs. 66:950.
    133. Brain Metastasis from Solid Tumors. 3-29.
    134. Breast cancer in the elderly. Cancer Bulletin. 47:212-217.
    135. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Breast Diseases. 24:224-225.
    136. Phase II Randomized Study of Ixabepilone Versus Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer. 15:325-331.
    137. TBCRC-010. Clinical Cancer Research. 22:5706-5712.
    138. Herceptin plus chemotherapy combination in preoperative regimen may offer clinical benefit in early stage breast cancer. Cancer Biology and Therapy. 4.
    139. Combinations of new and old agents for breast cancer treatment. Oncology. 10:30-36.
    140. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs.
    141. Brachial plexopathy and porencephaly in a patient with breast cancer. Cancer Bulletin. 46:185-188.
    142. Risk stratification in patients with advanced-stage breast cancer by pretreatment [<sup>18</sup>F]FDG PET/CT. Cancer.
    143. Ixabepilone development across the breast cancer continuum. Cancer Management and Research. 2:169-179.
    144. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Seminars in Oncology. 24.
    145. Glutathione S-transferase-pi expression in prechemotherapy and postchemotherapy tumor samples from patients with locally advanced breast carcinomas. Breast Journal. 2:246-252.
    146. A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer. Breast Diseases. 26:317-319.
    147. The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better. Translational Cancer Research. 5:S694-S696.
    148. Breast cancer with brainmetastases. Oncologist. 20:466-473.
    149. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer. Cancer.
    150. BAVITUXIMAB. Drugs of the Future. 40:281-286.
    151. Inflammatory breast cancer. PLoS One. 11.
    152. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Women's Oncology Review. 4:211-212.
    153. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal of Cancer. 113:1003-1009.
    IBRAHIM's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (429)
    Explore
    _
    Co-Authors (137)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _